Forum Alert: Pharmos Corporation will Present at the Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor For

Pharmos Corporation (NasdaqSC: PARSD) will present at
the following forum:
-0-
*T
What: Informed Investors Biotechnology / Healthcare / Pharmaceutical
      Investor Forum

When: June 15, 2005 @ 2:35 PM Eastern Time

Sponsors: Barron's, The Wall Street Journal, The American Stock
          Exchange and Business Wire

Keynote Presentations: Lynn Sutherland, M.S., M.B.A. - President,
                       Sutherland Consulting

                       Dr. Navdeep Jaikaria, Senior Biotechnology
                       Analyst, Rodman & Renshaw, LLC

Where: The Princeton Club of New York, 15 West 43rd Street., New York
       City, NY 10036

How to attend: Pre-registration is necessary. To register, contact
Cary Loeser, [e-mail], or 804-327-3407. You may also call
Customer Service at 888-301-6618, or register at the following link:
http://www.informedinvestors.com/CustomEvent/89559/index.asp

If you are unable to attend the live event, the forum will be
available via webcast at
http://www.informedinvestors.com/CustomEvent/89559/index.asp

Contact: Gale Smith, [e-mail], 732-452-9556 X204
*T

   Pharmos discovers and develops novel therapeutics to treat a range
of indications, in particular neurological and inflammatory disorders.
The Company's core proprietary technology platform focuses on
discovery and development of synthetic cannabinoid compounds.
Cannabinor, the lead CB2-selective receptor agonist candidate, is
scheduled to begin Phase I safety studies in the second half of 2005
and, if successful, enter Phase II testing in pain indications around
yearend or early 2006. From the dextrocannabinoid family, the
neuroprotective drug candidate dexanabinol recently completed a Phase
IIa trial as a preventive agent against post-surgical cognitive
impairment. Other compounds from Pharmos' proprietary synthetic
cannabinoid library are in pre-clinical studies targeting pain,
multiple sclerosis, rheumatoid arthritis and other disorders.